Journals / Kadın Doğum Dergisi / 2005 / Cilt: 3 - Sayı: 3

Comparison of the effects of intranasal estrogen and Cimicifuga racemosa extract administration on the vasomotor symptoms

Perimenopozal hastalarda Cimicifuga racemosa ekstresi ve intranazal östrojen tedavisinin klimakterik semptomlar üzerine etkinliklerinin karşılaştırılması

Pages
548–551
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However it should be accepted that cimicifuga racemosa is an alternative treatment not a subsitute of estrogens.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:With growing concern about the use of hormone replacement therapy, some women are looking for alternative treatments for menopausal symptoms and preventing post-menopausal cardiovascular disease and osteoporosis.
📊
Key Findings & Data:In observational trials, cimicifuga racemosa extract has been associated with decreased vasomotor symptoms, lower lipid levels, and increase bone density.
💡
Conclusion & Impact:However it should be accepted that cimicifuga racemosa is an alternative treatment not a subsitute of estrogens.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

With growing concern about the use of hormone replacement therapy, some women are looking for alternative treatments for menopausal symptoms and preventing post-menopausal cardiovascular disease and osteoporosis. In observational trials, cimicifuga racemosa extract has been associated with decreased vasomotor symptoms, lower lipid levels, and increase bone density. However, large amounts of it must be consumed, and it is not clear whether cimicifuga racemosa consumption causes a decrease in cardiovascular events or fractures. In the present study cimicifuga racemosa and intranasal estrogen application was compared for their effect on the vasomotor symptoms. It is found that in both group vasomotor symptoms was significantly decreased after 12 weeks of administration. However it should be accepted that cimicifuga racemosa is an alternative treatment not a subsitute of estrogens.

Özet

Estrojen kullanımına ait yan etkilerin abartılı bir şekilde medyaya yansıması sonucu hormon replasman tedavisi kullanmak istemeyen kadınlar için çeşitli alternatif tedaviler önerilmektedir. Bunlar arasında cimicifuga racemosa ekstreleriyle yapılan gözlemsel çalışmalar vazomotor semptomları azalttığını hatta kemik yoğunluğunu artırırken lipid seviyesini düşürdüğünü de göstermektedir. Ancak cimicifuga racemosa kullanımının gerçekten kardiyovasküler sistemi olumlu etkileyip etkilemediği yada kırıkları önleyip önlemediği bilinmemektedir. Sunulan çalışmada perimenapozal kadınlarda intranazal estrojen uygulamasıyla cimicifuga racemosa ekstresi tedavisinin vazomotor semptomlar üzerindeki etkileri karşılaştırılmaktadır. 12 haftalık tedavi sonunda her iki hasta grubunda da vazamotor semptomların önemli oranda azaldığı görülmektedir. Gruplar arasındaki farkta önemsizdir. Ancak cimicifuga racemosa ekstresinin estrojenin yerine geçen bir tedavi olarak görülmemesi yalnızca ve alternatif tedavi gereken hastalara verilmesi daha uygundur.

🔖

Cite This Article

AKHAN, S., İYİBOZKURT, C., ERGUN, B., DELİER, H. (2022). Comparison of the effects of intranasal estrogen and Cimicifuga racemosa extract administration on the vasomotor symptoms. Kadın Doğum Dergisi, Cilt: 3 - Sayı: 3, 548–551. https://ajindex.com/articles/569071

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Taylor M. Alternative medicine and the perimenopause: An evidence based review. ObstetGynecol ClinN Am 2002
  2. 573 2-Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms in quality of life. Br Med J 1993
  3. 840 3-Riggs BI, Melton LJ. The prevention and treatment of osteoporosis. N Engl J Med 1992
  4. 7 4-Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002
  5. 288(3):321-33 5-Hulley S, et al. Noncardiovascular disease outcomes dating 6.8 years of hormone replacement therapy. Heart and estrogen/progestin replacement study folllow-up (HERS II), J Am Med Assoc 2002
  6. 288(l): 58-66 6-Lizke E, Boblitz N, Henneicke-von Zepelin HH. Therapy of climacteric complaints with Cimicifuga racemosa: data on effect and efficacy from a randomized controlled double blind study, In: Rietbrock N, Donath MF, Loew D, Roots I, Schulz V, editors. Phitopharmaka VI. Darmstadt Steinkopff, 2002:247-57 7-Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. Cimicifuga and Melbroisa lack oestrogenic effects in mice and rats.Maturitas 1996
  7. 53 8-Kruse SO, Löhning A, Pauli GF, Winterhoff H, Nahrstedt A. Fukiic and piscidic acid esters from the rhizome of Cimicifuga racemosa and the in vitro estrogenic activity offukinolic acid. Planta Med 1999
  8. 65(8): 763-4 9-Munoz GH, Pluchino S. Cimcifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003
  9. 44suppll:S59-S65 10-Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimcifuga preparation BNO 1055 vs conjugated estrogens in a double-blind placebo controlled study: effects on menopause symptoms and bone markers. Maturitas 2003
  10. 44 suppl 1:S67-77 11-Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953
  11. 703 12-Panay N, Toth K, Pelissier C, Studd J. Dose ranging studies of a novel intranasal estrogen replacement therapy. Maturitas 2001
  12. 38 suppl1:S15-S22 13-Dooley M, Spencer CM, Ormrod D. Estradiol-intranasal: a review of its use in management of menopause. Drugs 2001
  13. 61(15):2243-62 14-Lopes P,etal. Aerodiol versus the transdermal route: perspectives for patient preferences. Maturitas 2001
  14. 38 suppl 1:S31-S39 15-LopesP,etal. Randomized comparison of intranasal and transdermalestradiol. ObstetGynecol 2000
  15. 912 16-Özsoy M, Oral B, Özsoy D. Clini